← Leaderboards
Meenhard Herlyn
University Of Pennsylvania
$50,214,821
Attributed
$54,241,845
Total exposure
51
Grants
42
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $11.4M · FY2005–25$20M$15M$10M$5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$159,522,011 · 57
By mechanism
P01$73,784,743 · 21
P50$45,616,266 · 12
R01$21,353,462 · 7
U54$17,192,304 · 13
RC1$959,491 · 1
P30$600,745 · 2
Top collaborators
- Michael Davies13 shared
- Arjun Raj9 shared
- Ravi K Amaravadi5 shared
- Ashani T Weeraratna5 shared
- Xiaowei Xu5 shared
- Markus Schober3 shared
- Jessie Villanueva3 shared
- Julide T Celebi1 shared
Most similar at University Of Pennsylvania
Same institution · by research overlap
- Xiaowei Xu$9,845,570
- Ronen Marmorstein$40,497,435
- Arjun Raj$12,538,737
- Peter J Felsburg$7,232,052
- Robert W. Doms$20,416,408
Others in their field
Top investigators on “Melanoma”
- David Heimbrook · Leidos Biomedical Research, Inc.$206,517,726
- Richard L Schilsky · University Of Chicago$108,377,382
- Larry Arthur$59,113,709
- Charles A Coltman · Southwest Oncology Group$55,198,633
- Robert L Comis · Frontier Sci &Technology Rsch Fdn, Inc$47,956,689
- Walter C. Willett · Harvard University (Sch Of Public Hlth)$34,125,742
Research focus
MelanomaProgramsResearch PersonnelCellsTumorMelanoma CellBiologicalBaseNeoplastic CellDesignBraf GeneResponseMutationIn VivoPathway InteractionsLaboratoriesCancer CellTargeted TreatmentGrowthBiologyMalignant NeoplasmsResourcesSignal TransductionGenes
Grant awards (200)
SPORE in Skin Cancer$2,351,294
P50 · FY2025 · CA · contact PI
Rational Approaches to Melanoma Therapy$1,284,372
U54 · FY2025 · CA
Gamma delta T cell based melanoma therapies$634,246
R01 · FY2025 · CA
Dissecting Phenotype Switching in Early Stage Melanomas$625,456
R01 · FY2025 · CA
Neoadjuvant immunotherapy approaches to early stage melanoma$474,126
P50 · FY2025 · CA · contact PI
Administrative Core$208,144
P50 · FY2025 · CA · contact PI
PDX Core$185,229
U54 · FY2025 · CA · contact PI
Pilot-Trans Network Core$183,984
U54 · FY2025 · CA · contact PI
Developmental Research Program$89,291
P50 · FY2025 · CA · contact PI
SPORE in Skin Cancer$2,257,242
P50 · FY2024 · CA · contact PI
Rational Approaches to Melanoma Therapy$1,220,153
U54 · FY2024 · CA
Gamma delta T cell based melanoma therapies$608,024
R01 · FY2024 · CA
Dissecting Phenotype Switching in Early Stage Melanomas$594,183
R01 · FY2024 · CA
Understanding and Overcoming Resistance to BRAF/MEK Kinase Inhibitors in Melanoma$478,669
R01 · FY2024 · CA
Neoadjuvant immunotherapy approaches to early stage melanoma$455,161
P50 · FY2024 · CA · contact PI
Administrative Core$199,819
P50 · FY2024 · CA · contact PI
PDX Core$177,298
U54 · FY2024 · CA · contact PI
Pilot-Trans Network Core$174,784
U54 · FY2024 · CA · contact PI
Developmental Research Program$85,719
P50 · FY2024 · CA · contact PI
Understanding and Overcoming Resistance to BRAF/MEK Kinase Inhibitors in Melanoma$69,233
R01 · FY2024 · CA
Targeted Therapies in Melanoma$2,478,587
P01 · FY2023 · CA · contact PI
SPORE in Skin Cancer$2,186,705
P50 · FY2023 · CA · contact PI
Rational Approaches to Melanoma Therapy$635,508
U54 · FY2023 · CA
Gamma delta T cell based melanoma therapies$632,718
R01 · FY2023 · CA
Dissecting Phenotype Switching in Early Stage Melanomas$612,946
R01 · FY2023 · CA
Understanding and Overcoming Resistance to BRAF/MEK Kinase Inhibitors in Melanoma$493,786
R01 · FY2023 · CA
Neoadjuvant immunotherapy approaches to early stage melanoma$440,937
P50 · FY2023 · CA · contact PI
Biology Core$272,984
P01 · FY2023 · CA · contact PI
Administrative Core$193,575
P50 · FY2023 · CA · contact PI
Explore Gamma delta T cell-based glioblastoma therapies$158,750
R01 · FY2023 · CA
Administrative Core$146,166
P01 · FY2023 · CA · contact PI
Understanding and Overcoming Resistance to BRAF/MEK Kinase Inhibitors in Melanoma$116,686
R01 · FY2023 · CA
PDX Core$112,092
U54 · FY2023 · CA · contact PI
Developmental Research Program$83,039
P50 · FY2023 · CA · contact PI
Pilot-Trans Network Core$12,027
U54 · FY2023 · CA · contact PI
Targeted Therapies in Melanoma$2,448,186
P01 · FY2022 · CA · contact PI
SPORE in Skin Cancer$2,194,229
P50 · FY2022 · CA · contact PI
Dissecting Phenotype Switching in Early Stage Melanomas$670,266
R01 · FY2022 · CA
Gamma delta T cell based melanoma therapies$666,701
R01 · FY2022 · CA
Rational approaches to melanoma therapy$589,729
U54 · FY2022 · CA · contact PI
Understanding and Overcoming Resistance to BRAF/MEK Kinase Inhibitors in Melanoma$493,785
R01 · FY2022 · CA
Neoadjuvant immunotherapy approaches to early stage melanoma$440,235
P50 · FY2022 · CA · contact PI
Biology Core$326,819
P01 · FY2022 · CA · contact PI
Administrative Core$197,388
P50 · FY2022 · CA · contact PI
Research Project 1 - Targeting the MAPK and PI3K pathways in melanoma PDX$144,672
U54 · FY2022 · CA · contact PI
Pilot Projects and Trans-Network Activities Core$124,749
U54 · FY2022 · CA · contact PI
Understanding and Overcoming Resistance to BRAF/MEK Kinase Inhibitors in Melanoma$119,069
R01 · FY2022 · CA
PDX Core$94,085
U54 · FY2022 · CA · contact PI
Developmental Research Program$88,354
P50 · FY2022 · CA · contact PI
Administrative Core$84,142
P01 · FY2022 · CA · contact PI
Administrative Core$70,392
U54 · FY2022 · CA · contact PI
Targeted Therapies in Melanoma$2,487,446
P01 · FY2021 · CA · contact PI
SPORE in Skin Cancer$2,323,912
P50 · FY2021 · CA · contact PI
Rational approaches to melanoma therapy$1,391,843
U54 · FY2021 · CA · contact PI
Understanding and Overcoming Resistance to BRAF/MEK Kinase Inhibitors in Melanoma$510,510
R01 · FY2021 · CA
Neoadjuvant immunotherapy approaches to early stage melanoma$466,650
P50 · FY2021 · CA · contact PI
Research Project 1 - Targeting the MAPK and PI3K pathways in melanoma PDX$344,048
U54 · FY2021 · CA · contact PI
Biology Core$335,055
P01 · FY2021 · CA · contact PI
PDX Core$313,602
U54 · FY2021 · CA · contact PI
Administrative Core$217,902
P50 · FY2021 · CA · contact PI
Pilot Projects and Trans-Network Activities Core$209,424
U54 · FY2021 · CA · contact PI
Administrative Core$125,459
U54 · FY2021 · CA · contact PI
Administrative Core$120,000
U54 · FY2021 · CA · contact PI
Rational approaches to melanoma therapy (PDXNet Administrative Supplement to R01CA241148)$120,000
U54 · FY2021 · CA · contact PI
Rational approaches to melanoma therapy (PDXNet Administrative Supplement to R01CA121118)$120,000
U54 · FY2021 · CA · contact PI
Administrative Core$120,000
U54 · FY2021 · CA · contact PI
Administrative Core$85,811
P01 · FY2021 · CA · contact PI
Developmental Research Program$85,109
P50 · FY2021 · CA · contact PI
Understanding and Overcoming Resistance to BRAF/MEK Kinase Inhibitors in Melanoma$46,189
R01 · FY2021 · CA
Targeted Therapies in Melanoma$2,498,687
P01 · FY2020 · CA · contact PI
Rational approaches to melanoma therapy$1,400,393
U54 · FY2020 · CA · contact PI
Understanding and Overcoming Resistance to BRAF/MEK Kinase Inhibitors in Melanoma$522,831
R01 · FY2020 · CA
Research Project 1 - Targeting the MAPK and PI3K pathways in melanoma PDX$352,598
U54 · FY2020 · CA · contact PI
PDX Core$313,602
U54 · FY2020 · CA · contact PI
Biology Core$306,029
P01 · FY2020 · CA · contact PI
Pilot Projects and Trans-Network Activities Core$209,424
U54 · FY2020 · CA · contact PI
Administrative Core$125,459
U54 · FY2020 · CA · contact PI
Administrative Core$79,713
P01 · FY2020 · CA · contact PI
Targeted Therapies in Melanoma$2,538,781
P01 · FY2019 · CA · contact PI
Rational approaches to melanoma therapy$1,430,873
U54 · FY2019 · CA · contact PI
Pilot Projects and Trans-Network Activities Core$391,385
U54 · FY2019 · CA · contact PI
Research Project 1 - Targeting the MAPK and PI3K pathways in melanoma PDX$354,878
U54 · FY2019 · CA · contact PI
Biology Core$344,322
P01 · FY2019 · CA · contact PI
Administrative Core$125,459
U54 · FY2019 · CA · contact PI
Rational approaches to melanoma therapy$119,969
U54 · FY2019 · CA · contact PI
Rational approaches to melanoma therapy$119,969
U54 · FY2019 · CA · contact PI
Administrative Core$85,756
P01 · FY2019 · CA · contact PI
Rational approaches to melanoma therapy$36,000
U54 · FY2019 · CA · contact PI
Administrative Core$19,996
U54 · FY2019 · CA · contact PI
Administrative Core$19,996
U54 · FY2019 · CA · contact PI
Research Project 1 - Targeting the MAPK and PI3K pathways in melanoma PDX$19,994
U54 · FY2019 · CA · contact PI
Pilot Projects and Trans-Network Activities Core$19,994
U54 · FY2019 · CA · contact PI
Pilot Projects and Trans-Network Activities Core$19,994
U54 · FY2019 · CA · contact PI
Research Project 1 - Targeting the MAPK and PI3K pathways in melanoma PDX$19,994
U54 · FY2019 · CA · contact PI
Pilot Projects and Trans-Network Activities Core$6,001
U54 · FY2019 · CA · contact PI
Research Project 1 - Targeting the MAPK and PI3K pathways in melanoma PDX$6,001
U54 · FY2019 · CA · contact PI
Administrative Core$5,999
U54 · FY2019 · CA · contact PI
SPORE in Skin Cancer$2,300,000
P50 · FY2018 · CA · contact PI
The role of genetic susceptibility in melanoma development$404,587
R01 · FY2018 · CA · contact PI
Targeted Combination Therapy for Melanoma$361,118
P50 · FY2018 · CA · contact PI
Administrative Core$226,737
P50 · FY2018 · CA · contact PI
Rational approaches to melanoma therapy$2,885,586
U54 · FY2017 · CA · contact PI
Targeted Therapies in Melanoma$2,498,463
P01 · FY2017 · CA · contact PI
SPORE in Skin Cancer$2,300,000
P50 · FY2017 · CA · contact PI
Research Project 1 - Targeting the MAPK and PI3K pathways in melanoma PDX$700,949
U54 · FY2017 · CA · contact PI
Senescence as a Therapeutic Endpoint$477,725
P01 · FY2017 · CA · contact PI
The role of genetic susceptibility in melanoma development$404,587
R01 · FY2017 · CA · contact PI
Administrative Core$360,188
U54 · FY2017 · CA · contact PI
Targeted Combination Therapy for Melanoma$353,850
P50 · FY2017 · CA · contact PI
Core C: Cell Biology Core$314,103
P01 · FY2017 · CA · contact PI
Pilot Projects and Trans-Network Activities Core$254,153
U54 · FY2017 · CA · contact PI
Administrative Core$221,323
P50 · FY2017 · CA · contact PI
Core D: Medicinal Chemistry Core$196,946
P01 · FY2017 · CA · contact PI
Core A: Administrative Core$150,493
P01 · FY2017 · CA · contact PI
Core E: Biostatistics Core$132,881
P01 · FY2017 · CA · contact PI
Core B: Pathology Core$105,201
P01 · FY2017 · CA · contact PI
Targeted Therapies in Melanoma$70,811
P01 · FY2017 · CA · contact PI
Targeted Therapies in Melanoma$2,496,009
P01 · FY2016 · CA · contact PI
SPORE in Skin Cancer$2,162,000
P50 · FY2016 · CA · contact PI
Senescence as a Therapeutic Endpoint$477,787
P01 · FY2016 · CA · contact PI
The role of genetic susceptibility in melanoma development$407,725
R01 · FY2016 · CA · contact PI
Core C: Cell Biology Core$311,673
P01 · FY2016 · CA · contact PI
Targeted Combination Therapy for Melanoma$269,632
P50 · FY2016 · CA · contact PI
Core D: Medicinal Chemistry Core$196,971
P01 · FY2016 · CA · contact PI
Administrative Core$155,886
P50 · FY2016 · CA · contact PI
Core A: Administrative Core$150,513
P01 · FY2016 · CA · contact PI
Core E: Biostatistics Core$132,899
P01 · FY2016 · CA · contact PI
Core B: Pathology Core$105,214
P01 · FY2016 · CA · contact PI
Targeted Therapies in Melanoma$93,311
P01 · FY2016 · CA · contact PI
Targeted Therapies in Melanoma$2,485,489
P01 · FY2015 · CA · contact PI
SPORE in Skin Cancer$2,185,000
P50 · FY2015 · CA · contact PI
Human Melanoma: Etiology, Progression and Therapy$1,422,871
P01 · FY2015 · CA · contact PI
Senescence as a Therapeutic Endpoint$478,108
P01 · FY2015 · CA · contact PI
The role of genetic susceptibility in melanoma development$401,931
R01 · FY2015 · CA · contact PI
Cellular Mechanisms of Therapy Resistance in Melanoma$375,217
P01 · FY2015 · CA · contact PI
Targeted Combination Therapy for Melanoma$334,517
P50 · FY2015 · CA · contact PI
Biology of Melanoma Metastasis$329,003
R01 · FY2015 · CA · contact PI
Core C: Cell Biology Core$306,670
P01 · FY2015 · CA · contact PI
Cell-cell communication during melanoma development$284,153
R01 · FY2015 · CA · contact PI
Administrative Core$207,511
P50 · FY2015 · CA · contact PI
Core D: Medicinal Chemistry Core$197,103
P01 · FY2015 · CA · contact PI
Core A: Administrative Core$150,612
P01 · FY2015 · CA · contact PI
Administrative Core$140,097
P01 · FY2015 · CA · contact PI
Core E: Biostatistics Core$132,988
P01 · FY2015 · CA · contact PI
Core B: Pathology Core$105,285
P01 · FY2015 · CA · contact PI
Targeted Therapies in Melanoma$2,404,014
P01 · FY2014 · CA · contact PI
SPORE in Skin Cancer$2,162,000
P50 · FY2014 · CA · contact PI
Human Melanoma: Etiology, Progression and Therapy$1,438,284
P01 · FY2014 · CA · contact PI
Senescence as a Therapeutic Endpoint$460,322
P01 · FY2014 · CA · contact PI
The role of genetic susceptibility in melanoma development$435,258
R01 · FY2014 · CA · contact PI
Cellular Mechanisms of Therapy Resistance in Melanoma$364,881
P01 · FY2014 · CA · contact PI
Targeted Combination Therapy for Melanoma$325,329
P50 · FY2014 · CA · contact PI
Biology of Melanoma Metastasis$319,132
R01 · FY2014 · CA · contact PI
Core C: Cell Biology Core$293,912
P01 · FY2014 · CA · contact PI
Cell-cell communication during melanoma development$275,821
R01 · FY2014 · CA · contact PI
Administrative Core$211,507
P50 · FY2014 · CA · contact PI
Core D: Medicinal Chemistry Core$198,650
P01 · FY2014 · CA · contact PI
Core A: Administrative Core$145,010
P01 · FY2014 · CA · contact PI
Core E: Biostatistics Core$128,040
P01 · FY2014 · CA · contact PI
Administrative Core$126,540
P01 · FY2014 · CA · contact PI
Core B: Pathology Core$101,369
P01 · FY2014 · CA · contact PI
Targeted Therapies in Melanoma$2,567,345
P01 · FY2013 · CA · contact PI
Human Melanoma: Etiology, Progression and Therapy$1,352,759
P01 · FY2013 · CA · contact PI
Senescence as a Therapeutic Endpoint$487,328
P01 · FY2013 · CA · contact PI
Cellular Mechanisms of Therapy Resistance in Melanoma$340,035
P01 · FY2013 · CA · contact PI
Core C: Cell Biology Core$311,228
P01 · FY2013 · CA · contact PI
Biology of Melanoma Metastasis$288,936
R01 · FY2013 · CA · contact PI
Cell-cell communication during melanoma development$250,396
R01 · FY2013 · CA · contact PI
Core D: Medicinal Chemistry Core$232,523
P01 · FY2013 · CA · contact PI
Core A: Administrative Core$153,518
P01 · FY2013 · CA · contact PI
Core E: Biostatistics Core$135,553
P01 · FY2013 · CA · contact PI
Administrative Core$115,727
P01 · FY2013 · CA · contact PI
Core B: Pathology Core$107,316
P01 · FY2013 · CA · contact PI
The Tumor Microenvironment in Esophageal Squamous Cell Carcinoma$61,228
P01 · FY2013 · CA · contact PI
Targeted Therapies in Melanoma$2,395,590
P01 · FY2012 · CA · contact PI
Human Melanoma: Etiology, Progression and Therapy$1,421,890
P01 · FY2012 · CA · contact PI
Targeting the MAP and PI3 Kinase Pathways in Melanoma$486,670
P01 · FY2012 · CA · contact PI
Cellular Mechanisms of Therapy Resistance in Melanoma$362,782
P01 · FY2012 · CA · contact PI
Biology of Melanoma Metastasis$305,670
R01 · FY2012 · CA · contact PI
Cell-cell communication during melanoma development$263,346
R01 · FY2012 · CA · contact PI
Cell Biology Core$177,783
P01 · FY2012 · CA · contact PI
Administrative Core$124,422
P01 · FY2012 · CA · contact PI
The Tumor Microenvironment in Esophageal Squamous Cell Carcinoma$65,249
P01 · FY2012 · CA · contact PI
Targeted Therapies in Melanoma$2,355,621
P01 · FY2011 · CA · contact PI
Human Melanoma: Etiology, Progression and Therapy$1,469,332
P01 · FY2011 · CA · contact PI
Targeting the MAP and PI3 Kinase Pathways in Melanoma$478,396
P01 · FY2011 · CA · contact PI
Cellular Mechanisms of Therapy Resistance in Melanoma$382,016
P01 · FY2011 · CA · contact PI
Biology of Melanoma Metastasis$317,738
R01 · FY2011 · CA · contact PI
Cell-cell communication during melanoma development$279,784
R01 · FY2011 · CA · contact PI
Cell Biology Core$174,287
P01 · FY2011 · CA · contact PI
Administrative Core$143,886
P01 · FY2011 · CA · contact PI
The Tumor Microenvironment in Esophageal Squamous Cell Carcinoma$65,081
P01 · FY2011 · CA · contact PI
Targeted Therapies in Melanoma$2,542,174
P01 · FY2010 · CA · contact PI
Targeting the MAP and PI3 Kinase Pathways in Melanoma$516,128
P01 · FY2010 · CA · contact PI
3D human skin models$472,266
RC1 · FY2010 · ES · contact PI
Cell-Cell Communication During Melanoma Development$276,316
R01 · FY2010 · CA · contact PI
Cell Biology Core$187,857
P01 · FY2010 · CA · contact PI
The Tumor Microenvironment in Esophageal Squamous Cell Carcinoma$66,445
P01 · FY2010 · CA · contact PI
Targeted Therapies in Melanoma$2,374,988
P01 · FY2009 · CA · contact PI
Human Melanoma - Etiology, Progression and Therapy$1,342,967
P01 · FY2009 · CA · contact PI